GSK3923868

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic ObstructiveRespiratory Tract Infections

Phase 1

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

CompletedNCT04585009

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2020-10-12End: 2022-06-16Updated: 2024-02-20

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma

CompletedNCT05398198

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2022-06-09End: 2024-04-09Updated: 2024-05-06

Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT05677347

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2023-01-23End: 2023-07-20Updated: 2024-10-15

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

CompletedNCT06577597

GlaxoSmithKlineRespiratory Tract Infections

Start: 2024-09-02End: 2024-11-01Updated: 2024-12-10

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

CompletedNCT06597500

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2024-09-30End: 2024-12-23Updated: 2025-03-07